CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies
Endocrine malignancies constitute a heterogeneous tumour group with diverse biological characteristics. While typically indolent, they encompass aggressive types and presence of any metastatic sign indicates a high probability of recurrence and a diminished response to conventional therapies. Chimer...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1517525/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859400643706880 |
|---|---|
| author | Fang Wang Ruiqi Zhang Zhaokai Zhou Run Shi Fu Peng Yudi Xu Shuai Yang Zhan Wang Pengpeng Zhang Rui Tu Chun Zhang Xingchen Liu Jun Cai |
| author_facet | Fang Wang Ruiqi Zhang Zhaokai Zhou Run Shi Fu Peng Yudi Xu Shuai Yang Zhan Wang Pengpeng Zhang Rui Tu Chun Zhang Xingchen Liu Jun Cai |
| author_sort | Fang Wang |
| collection | DOAJ |
| description | Endocrine malignancies constitute a heterogeneous tumour group with diverse biological characteristics. While typically indolent, they encompass aggressive types and presence of any metastatic sign indicates a high probability of recurrence and a diminished response to conventional therapies. Chimeric antigen receptor (CAR)-T cell immunotherapy has constituted a revolutionary advance in cancer treatment and exhibited significant potential for application in endocrine cancer. However, limited effectiveness was displayed in clinical application, which necessitates the exploration of novel modalities. Identification of specific and safe targets for endocrine cancer is the initial stage towards establishing a successful CAR-T treatment. Various therapies under investigation offer potential enhancements to CAR T cell efficacy through diverse mechanisms. Herein, we summarize recent advances in identifying targets of endocrine cancer for CAR therapy and provide an overview of combinatorial approaches. |
| format | Article |
| id | doaj-art-6e33e2b8ac6b4b31a168d3d2b2a8b2a4 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-6e33e2b8ac6b4b31a168d3d2b2a8b2a42025-02-11T05:10:24ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-02-011610.3389/fendo.2025.15175251517525CAR-T therapy for endocrine neoplasms: novel targets and combination of therapiesFang Wang0Ruiqi Zhang1Zhaokai Zhou2Run Shi3Fu Peng4Yudi Xu5Shuai Yang6Zhan Wang7Pengpeng Zhang8Rui Tu9Chun Zhang10Xingchen Liu11Jun Cai12Department of Otolaryngology-Head and Neck Surgery, Xinyang Central Hospital, Xinyang, Henan, ChinaDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Henan Joint International Pediatric Urodynamic Laboratory, Zhengzhou, ChinaDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Henan Joint International Pediatric Urodynamic Laboratory, Zhengzhou, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Pharmacology, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Henan Joint International Pediatric Urodynamic Laboratory, Zhengzhou, ChinaDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Henan Joint International Pediatric Urodynamic Laboratory, Zhengzhou, ChinaDepartment of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Ultrasound, Xinyang Central Hospital, Xinyang, Henan, ChinaDepartment of Gastroenterology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Gynaecology, Xinyang Central Hospital, Xinyang, Henan, ChinaDepartment of Gynaecology, Xinyang Central Hospital, Xinyang, Henan, ChinaEndocrine malignancies constitute a heterogeneous tumour group with diverse biological characteristics. While typically indolent, they encompass aggressive types and presence of any metastatic sign indicates a high probability of recurrence and a diminished response to conventional therapies. Chimeric antigen receptor (CAR)-T cell immunotherapy has constituted a revolutionary advance in cancer treatment and exhibited significant potential for application in endocrine cancer. However, limited effectiveness was displayed in clinical application, which necessitates the exploration of novel modalities. Identification of specific and safe targets for endocrine cancer is the initial stage towards establishing a successful CAR-T treatment. Various therapies under investigation offer potential enhancements to CAR T cell efficacy through diverse mechanisms. Herein, we summarize recent advances in identifying targets of endocrine cancer for CAR therapy and provide an overview of combinatorial approaches.https://www.frontiersin.org/articles/10.3389/fendo.2025.1517525/fullendocrine neoplasmschimeric antigen receptor T cellimmunotherapycombined immunotherapyclinical trials |
| spellingShingle | Fang Wang Ruiqi Zhang Zhaokai Zhou Run Shi Fu Peng Yudi Xu Shuai Yang Zhan Wang Pengpeng Zhang Rui Tu Chun Zhang Xingchen Liu Jun Cai CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies Frontiers in Endocrinology endocrine neoplasms chimeric antigen receptor T cell immunotherapy combined immunotherapy clinical trials |
| title | CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies |
| title_full | CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies |
| title_fullStr | CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies |
| title_full_unstemmed | CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies |
| title_short | CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies |
| title_sort | car t therapy for endocrine neoplasms novel targets and combination of therapies |
| topic | endocrine neoplasms chimeric antigen receptor T cell immunotherapy combined immunotherapy clinical trials |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1517525/full |
| work_keys_str_mv | AT fangwang carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT ruiqizhang carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT zhaokaizhou carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT runshi carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT fupeng carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT yudixu carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT shuaiyang carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT zhanwang carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT pengpengzhang carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT ruitu carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT chunzhang carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT xingchenliu carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies AT juncai carttherapyforendocrineneoplasmsnoveltargetsandcombinationoftherapies |